SUNPHARMA — Sun Pharmaceutical Industries Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Sun Pharmaceutical Industries, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	334,981	386,545	438,857	484,969	525,784
Cost of Revenue
Gross Profit	236,127	269,468	319,433	364,272	403,809
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	313,515	350,768	347,933	384,799	406,745
Operating Profit	21,466	35,777	90,924	100,169	119,039
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	27,994	44,813	94,084	110,879	137,521
Provision for Income Taxes
Net Income After Taxes	22,847	34,058	85,608	96,484	109,801
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	29,038	32,727	84,736	95,764	109,290
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	29,038	32,727	84,736	95,764	109,290
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	26.7	28	36	41.7	47.9
Dividends per Share